CMO
Team
Hans Eriksson serves as Chief Medical Officer of FundaMental Pharma.
Hans Eriksson brings more than 25 years of clinical development experience across pharma and biotech, including leading clinical development programs at AstraZeneca, Lundbeck, COMPASS Pathways and HMNC Brain Health.
He has contributed to eight late-phase clinical development programs in depression, three of which have resulted in regulatory approvals for Major Depressive Disorder (MDD). Most recently, Hans Eriksson served as Chief Medical Officer of HMNC Brain Health, where he led three depression programs, including Ketabon (KET01), an oral prolonged‑release formulation of ketamine for treatment-resistant depression (TRD).
Before that, he was Chief Medical Officer of COMPASS Pathways, where he led the clinical development of the psychedelic treatment psilocybin (COMP360), for TRD.
He has held senior clinical research and leadership roles at AstraZeneca, where he was the global medical lead for Seroquel, Seroquel XR and TC5214, and at Lundbeck, being the clinical lead for the co-development of brexpiprazole for depression.
Hans Eriksson holds an MD and PhD from Lund University in Sweden, and an Executive MBA from the Stockholm School of Economics, and has a clinical background as a consultant psychiatrist working with patients with depression and schizophrenia.
